- RecruitingPHASE3
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for children and teenagers aged 2 to 17 with moderately to severely active Crohn's disease. It checks how well the medicine works after a year in those who responded early on.
For: Crohn's DiseaseUnited States · Australia · Austria - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
For: Crohn's DiseaseUnited States · Australia · Austria - RecruitingPHASE3
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
This study compares two medicines, guselkumab and risankizumab, for people with moderate to severe Crohn's disease. Researchers want to see which one works better to reduce inflammation in the gut and improve symptoms.
For: Crohn DiseaseUnited States · Austria · Belgium - Active not recruiting
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
This study looks at how well new and existing treatments for Psoriatic Arthritis, called guselkumab and IL-17 inhibitors, work in people's everyday lives. It aims to understand how long people stay on these medicines and their real-world impact.
For: Arthritis, PsoriaticArgentina · Australia · Austria - Active not recruitingPHASE2, PHASE3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called guselkumab for people with ulcerative colitis that isn't well-controlled. We want to see if it helps reduce symptoms and if it's safe to use for those with moderate to severe forms of the condition.
For: Ulcerative ColitisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
This study is looking into two medicines, ustekinumab and guselkumab, for children and young people aged 5-17 with juvenile psoriatic arthritis. We want to see how well these medicines work, if they are safe, and how the body handles them to help manage this type of arthritis.
For: Arthritis, JuvenileUnited States · Argentina · Denmark - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
For: Crohn's DiseaseUnited States · Australia · Austria - Active not recruitingPHASE3
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
This study looks at how a medicine called guselkumab helps people with Crohn's disease. Researchers want to see if it heals all layers of the gut and how well it works overall, using special scans to check progress.
For: Crohn's DiseaseUnited States · Australia · Belgium - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study looks at new ways to treat ulcerative colitis, a condition causing gut inflammation. We're testing a combination of medicines (JNJ-78934804) for people whose current treatments aren't working well. The goal is to see if these new approaches are safe and effective.
For: Colitis, UlcerativeUnited States · Argentina · Australia - RecruitingPHASE3
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
This study looks at the long-term safety of a medicine called guselkumab for children and young people with Crohn's disease, ulcerative colitis, or a type of arthritis called juvenile psoriatic arthritis. It's for those who have already seen benefits from the medicine in an earlier study.
For: Crohns Disease · Colitis, Ulcerative · Arthritis, PsoriaticUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
This study is looking at a new medicine called guselkumab for people with psoriatic arthritis. It aims to see how well it reduces pain, swelling, and other symptoms compared to a dummy treatment, and if it helps improve their condition.
For: Arthritis, PsoriaticUnited States · Australia · Bosnia and Herzegovina - Active not recruitingPHASE4
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
This study is looking at a new treatment called guselkumab for people with psoriatic arthritis that affects the spine and pelvis. It aims to see how well it reduces pain and inflammation in these areas. Participants will receive either the study drug or a dummy treatment.
For: Arthritis, PsoriaticUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
This study is testing a new medication called guselkumab for people with Crohn's disease who have problems with fistulas around the back passage. It aims to see how well the medication works and if it's safe compared to a dummy treatment.
For: Fistulizing Crohns Disease · Perianal Crohns DiseaseUnited States · Australia · Belgium - RecruitingPhase III
A long-term extension (LTE) study of guselkumab in pediatric participants
This study looks at the long-term safety of a medicine called guselkumab for children and young people aged 2-17 with Crohn's disease, ulcerative colitis, or a type of arthritis called juvenile psoriatic arthritis. It's for those who have already benefited from guselkumab in a previous study.
For: Moderately to severely active ulcerative colitis (UC), moderately to severely active Crohn's disease (CD), Juvenile psoriatic arthritis (jPsA)United Kingdom · Argentina · Australia